The foundation nobody explains.

Most men on testosterone replacement therapy are under-dosed, over-aromatized, and monitored by practitioners who have never read the Endocrine Society guidelines. The initiation protocol is not complicated. The standard of care is.

I. The dose most men are on is too low.

The standard "low normal" target of 350-500 ng/dL is a consensus of mediocrity. The Endocrine Society's 2018 clinical practice guideline targets the mid-normal range for symptomatic men. Mid-normal for a 45-year-old is 600-900 ng/dL. Most TRT practices target the floor, not the midpoint. verified

Injectable testosterone cypionate at 100 mg per week is the most commonly prescribed dose. For most men it produces a total testosterone around 500-600 ng/dL at trough. That is not replacement. It is suppression of endogenous production with a small offset added back. The man feels a fraction better and assumes the therapy is working. The prescriber calls it a success because the number is "in range."

In range is not the same as optimized. A symptomatic man with a testosterone of 510 ng/dL on therapy has not been treated. He has been moved off the floor and left on the stairs.

II. The estradiol question is the one your prescriber is most likely to answer incorrectly.

Estradiol (E2) is essential in men. Bone density, libido, cardiovascular function, and mood all depend on it. The practice of reflexively prescribing anastrozole to any man with an E2 above 30 pg/mL is not supported by evidence. verified Ref: Endocrine Society 2018; Finkelstein et al. NEJM 2013.

Finkelstein et al. demonstrated that suppressing estradiol in men while maintaining testosterone produced loss of libido and sexual function even at normal testosterone levels. verified The E2 is not the enemy. The ratio is. A man with testosterone at 850 ng/dL and estradiol at 45 pg/mL is typically functioning well. A man with testosterone at 850 ng/dL and estradiol at 12 pg/mL because his prescriber added anastrozole at initiation is not. He is dry, flat, depressed, and losing libido, and his prescriber may increase the testosterone dose in response, which compounds the problem.

III. Injectable vs. topical vs. pellet: the decision tree.

Injectable (cypionate, enanthate): the gold standard for dose control, monitoring, and cost. Weekly or twice-weekly injection produces predictable peaks and troughs. Twice-weekly split dosing reduces peak-to-trough variation and may reduce aromatization burden by avoiding the high-concentration peak that drives conversion. verified For most men pursuing optimization, injectable testosterone cypionate split twice weekly is the correct starting point. The pharmacokinetics are well characterized, the dose is adjustable, and the cost is low.

Topical (cream, gel): highly variable absorption. DHT conversion is significantly higher via skin application than via injection due to 5-alpha reductase activity in dermal tissue. verified For men with prostate sensitivity concerns or needle aversion, topical may be appropriate. For optimization, it is not first-line. Transfer risk to female partners and children is real and requires documented counseling. Absorption variability makes dose titration imprecise.

Pellet: see Operator Note V on the pellet pharmacokinetics problem. THE PIVOTAL PROTOCOL does not recommend pellets for testosterone initiation. inferred The first-order decay curve, the inability to adjust mid-cycle, and the requirement for minor surgery to remove make pellets an inferior delivery vehicle for any man who expects to have his protocol actively managed.

IV. The monitoring cadence that actually protects you.

The prescriber who draws labs once per year is not monitoring. They are documenting that they ordered labs once. The following cadence is what active management looks like.

Baseline before initiation: total testosterone, free testosterone, estradiol (sensitive assay, not standard immunoassay), hematocrit, PSA, LH, FSH, metabolic panel, lipid panel. No baseline means no reference point. No reference point means no ability to evaluate whether the intervention worked or caused harm.

Week 6-8: total testosterone, free testosterone, estradiol. This is the first dose adjustment window. The man is steady-state on the initial dose by week 4. Week 6-8 labs give a clean read on what the dose is producing and whether aromatase management is warranted. Not before. After.

Week 12: hematocrit. Erythrocytosis risk on testosterone is real and dose-dependent. verified Hematocrit above 54 percent carries documented thrombotic risk. The first hematocrit check at week 12 catches the early ramp before it becomes a clinical problem.

Every 6 months ongoing: full panel including hematocrit, testosterone, estradiol, PSA, and metabolic markers. The annual lab draw is not a monitoring protocol. It is the minimum required to maintain a DEA Schedule III prescription. It protects the prescriber. It does not protect the patient.

V. The hematocrit problem no one warns you about.

Testosterone stimulates erythropoiesis via the erythropoietin pathway. This is a physiologic effect, not a side effect. At therapeutic doses it is manageable. At higher doses or in men who already carry high-normal hematocrit at baseline, it can become a problem quickly. verified Ref: Endocrine Society 2018; Coviello et al. 2008.

Hematocrit above 54 percent carries real thrombotic risk. Therapeutic phlebotomy is the standard intervention. It is not optional and it is not a sign that the protocol failed. It is active management. The alternative is a man with a hematocrit of 55 percent, no monitoring, no intervention, and a pulmonary embolism at 52. This is not rare. It is underreported because the connection to testosterone therapy is frequently not documented in the event record.

Any man on testosterone therapy who has not had a hematocrit drawn in the last six months does not know whether he is at risk. Any prescriber who has not drawn one is not managing the protocol. They are writing prescriptions.

VI. How Pivotal builds the initiation protocol.

THE PIVOTAL PROTOCOL's approach to testosterone initiation follows a defined sequence. It does not begin with a prescription. It begins with a complete intake review: prior labs, symptom chronology, prior prescribers, current hormone status, current aromatase activity, and the man's own goals for therapy.

Starting dose recommendation: 140-200 mg per week split twice weekly for most men. Not 100 mg per week. The reason is that 100 mg per week produces trough levels that, for many men, remain in the symptomatic range. The purpose of initiating TRT is to bring the man into a range where the biology changes. That requires a dose that actually gets there.

No anastrozole at initiation. Labs at week 6 determine whether aromatase management is warranted, what form it should take, and at what dose. The decision is based on serum estradiol and symptoms, not on the calendar.

Monitoring calendar built into the protocol document. The man leaves intake with a defined schedule: week 6-8 labs, week 12 hematocrit, 6-month full panel. The calendar is not a suggestion. It is the protocol.

THE PIVOTAL PROTOCOL is a research and education operation. Nothing in this note constitutes medical advice, diagnosis, or treatment. All clinical decisions belong to a licensed physician with complete knowledge of the individual case. The mechanisms and references described here are derived from published literature cited above. Begin a conversation with a qualified prescriber. Do not begin self-administration from a website.